Discovery: Accelerate Innovation
Curia’s combined expertise and a proven track record of success in key scientific disciplines including molecular biology, protein production and analysis, enzymes, nucleosides and lipids is the foundation of our mRNA solution. Partner with us and harness our ability to provide high-quality constructs through in-house research and analysis capabilities that enable accelerated timelines for delivery.
Development: Amplify Ingenuity
Curia’s end-to-end capabilities extend from production of plasmid DNA and manufacturing of enzymes and nucleosides at gram-to-kilogram scale, to drug substance development through first-in-human clinical supply manufacturing. Our sites in California and Massachusetts provide capacity for reliable plasmid production for “traditional” and self-amplifying mRNA drug substance. First-in-human clinical-scale cGMP manufacturing is supplemented by in-house analytical capabilities for product testing and release.
Curia has a proven track record in the rapid development of numerous specialized lipids for mRNA applications and the ability to manufacture lipids to metric-ton scale in accordance with cGMP. Curia’s scientists have expertise in coupling synthesis with highly effective separations and purifications of APIs and functional excipients.
Curia’s mRNA solution includes complex formulation capabilities and experience in liposome and lipid nanoparticles led by its expert scientists.
Manufacturing: Meet patient demand
Maximize the impact of your product with our clinical and commercial aseptic sterile fill-finish capability and capacity. We provide process development and first-in-human clinical manufacturing through to full commercial manufacturing of mRNA injectable dosage products in accordance with cGMP.
Ready to move from idea to impact?
Whether you have a question for our team or an opportunity you’re eager to pursue, one of our experts can help you get started.Contact Us
More from Curia
Lyophilization: Protecting and preserving biologics
Lyophilization, also known as freeze-drying, is often a crucial step in the manufacturing process of biologics drug products. Biologics are large, complex molecules used to treat various diseases, including cancer, autoimmune disorders, and rare gene...
Rapid discovery and characterization of monoclonal antibodies against the SARS-CoV-2 Delta spike protein
In the fall of 2021, the Delta variant of SARS-CoV-2 was the dominant strain in the US, being both more contagious than previous variants and more likely to lead to “long COVID” than subsequent Omicron variants. Here we describe the discovery and...